Publication:
SEOM clinical guideline in ovarian cancer (2020).

dc.contributor.authorRedondo, A
dc.contributor.authorGuerra, E
dc.contributor.authorManso, L
dc.contributor.authorMartin-Lorente, C
dc.contributor.authorMartinez-Garcia, J
dc.contributor.authorPerez-Fidalgo, J A
dc.contributor.authorVarela, M Q
dc.contributor.authorRubio, M J
dc.contributor.authorBarretina-Ginesta, M P
dc.contributor.authorGonzalez-Martin, A
dc.date.accessioned2023-02-09T10:40:40Z
dc.date.available2023-02-09T10:40:40Z
dc.date.issued2021-01-30
dc.description.abstractDespite remarkable advances in the knowledge of molecular biology and treatment, ovarian cancer remains the leading cause of death from gynecologic cancer. In the last decade, there have been important advances both in systemic and surgical treatment. However, there is no doubt that the incorporation of PARP inhibitors as maintenance after the response to platinum-based chemotherapy, first in recurrent disease and recently also in first line, will change the natural history of the disease.The objective of this guide is to summarize the current evidence for the diagnosis, treatment, and follow-up of ovarian cancer, and to provide evidence-based recommendations for clinical practice.
dc.identifier.doi10.1007/s12094-020-02545-x
dc.identifier.essn1699-3055
dc.identifier.pmcPMC8058000
dc.identifier.pmid33515422
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8058000/pdf
dc.identifier.unpaywallURLhttps://link.springer.com/content/pdf/10.1007/s12094-020-02545-x.pdf
dc.identifier.urihttp://hdl.handle.net/10668/17069
dc.issue.number5
dc.journal.titleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
dc.journal.titleabbreviationClin Transl Oncol
dc.language.isoen
dc.organizationHospital Universitario Reina Sofía
dc.page.number961-968
dc.pubmedtypeJournal Article
dc.pubmedtypePractice Guideline
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectDiagnosis
dc.subjectGuideline
dc.subjectOvarian cancer
dc.subjectTreatment
dc.subject.meshAntineoplastic Agents, Immunological
dc.subject.meshBevacizumab
dc.subject.meshCarcinoma, Ovarian Epithelial
dc.subject.meshChemotherapy, Adjuvant
dc.subject.meshClinical Trials, Phase III as Topic
dc.subject.meshCytoreduction Surgical Procedures
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshMaintenance Chemotherapy
dc.subject.meshMedical Oncology
dc.subject.meshNeoplasm Recurrence, Local
dc.subject.meshNeoplasm Staging
dc.subject.meshOvarian Neoplasms
dc.subject.meshPoly(ADP-ribose) Polymerase Inhibitors
dc.subject.meshRandomized Controlled Trials as Topic
dc.subject.meshSocieties, Medical
dc.subject.meshSpain
dc.titleSEOM clinical guideline in ovarian cancer (2020).
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number23
dspace.entity.typePublication
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PMC8058000.pdf
Size:
543.83 KB
Format:
Adobe Portable Document Format